{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:04:15Z","timestamp":1789387455108,"version":"build-2803163510"},"reference-count":43,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/na","name":"Department of Education","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Graduate Assistance for Areas of National Need fellowship, Department of Education","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"NSF","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Poor distribution is often a limiting factor when using affinity targeted treatments. High affinity creates a barrier to transport because proteins cannot diffuse throughout the tissue while bound to the cell surface. Lowering the affinity can help with transport throughout a tumor but can also result in a loss of total delivery and specificity for the target. In this research, we used point mutations to create affibodies with a range of different affinities for epidermal growth factor receptor (EGFR) and measured their penetration through tumor spheroids. Mutants in the range of \u223c7\u201312 nM KD were able to distribute more evenly throughout 3D tumor spheroids without losing total accumulation or receptor specificity. Lower affinity mutants showed both low target specificity and accumulation in 3D tumor spheroids. This work shows the effects of affinity on distribution and how slightly reducing binding affinity can improve transport.<\/jats:p>","DOI":"10.1021\/acs.biomac.6c01111","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:01:13Z","timestamp":1787158873000},"page":"6134-6142","source":"Crossref","is-referenced-by-count":0,"title":["Optimization\nof Affibody Affinity to Improve Distribution in Tumor Models"],"prefix":"10.1021","volume":"27","author":[{"given":"Bryce M.","family":"Bower","sequence":"first","affiliation":[{"name":"University of Colorado , , , ,","place":["Boulder, Colorado, United States, 80303"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle M.","family":"Ho","sequence":"additional","affiliation":[{"name":"University of Colorado , , , ,","place":["Boulder, Colorado, United States, 80303"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven A.","family":"Saemundsson","sequence":"additional","affiliation":[{"name":"University of Colorado , , , ,","place":["Boulder, Colorado, United States, 80303"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-4005","authenticated-orcid":true,"given":"Andrew P.","family":"Goodwin","sequence":"additional","affiliation":[{"name":"University of Colorado , , , ,","place":["Boulder, Colorado, United States, 80303"]},{"name":"University of Colorado , , , ,","place":["Boulder, Colorado, United States, 80303"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2840-1653","authenticated-orcid":true,"given":"Jennifer N.","family":"Cha","sequence":"additional","affiliation":[{"name":"University of Colorado , , , ,","place":["Boulder, Colorado, United States, 80303"]},{"name":"University of Colorado , , , ,","place":["Boulder, Colorado, United States, 80303"]},{"name":"University of Colorado , , , ,","place":["Boulder, Colorado, United States, 80303"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026091407071843700_cit1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and Cancer Prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"2026091407071843700_cit2","first-page":"14","article-title":"Monoclonal\nAntibodies in Cancer Therapy","volume":"12","author":"Scott","year":"2012","journal-title":"Cancer Immun"},{"issue":"21","key":"2026091407071843700_cit3","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1038\/s41388-021-01811-8","article-title":"Antibody-Based Cancer Therapy","volume":"40","author":"Goydel","year":"2021","journal-title":"Oncogene"},{"issue":"3","key":"2026091407071843700_cit4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal Antibodies\nin Cancer Therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"issue":"1","key":"2026091407071843700_cit5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging New Therapeutic Antibody\nDerivatives for Cancer Treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct.\nTarget. Ther."},{"issue":"3","key":"2026091407071843700_cit6","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.35","article-title":"Affibody Molecules\nas Engineered Protein Drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Exp. Mol. Med."},{"issue":"8","key":"2026091407071843700_cit7","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1039\/D4NA00823E","article-title":"Affinity and Transport\nStudies of Engineered Photocrosslinkable\nAffibody-Enzyme-Nanoparticle Constructs","volume":"7","author":"Curry","year":"2025","journal-title":"Nanoscale\nAdv."},{"issue":"2","key":"2026091407071843700_cit8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.7150\/thno.37443","article-title":"Monoclonal Antibody-Based\nMolecular Imaging Strategies and Theranostic\nOpportunities","volume":"10","author":"Dammes","year":"2020","journal-title":"Theranostics"},{"key":"2026091407071843700_cit9","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3389\/fimmu.2017.01287","article-title":"Antibody or Antibody\nFragments: Implications for Molecular Imaging and Targeted Therapy\nof Solid Tumors","volume":"8","author":"Xenaki","year":"2017","journal-title":"Front. Immunol."},{"issue":"23","key":"2026091407071843700_cit10","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/cmdc.201800624","article-title":"Antibody\nFragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies\nand Applications","volume":"13","author":"Fu","year":"2018","journal-title":"ChemMedChem"},{"issue":"3","key":"2026091407071843700_cit11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Cetuximab\nand Chemotherapy in BRAF-Mutant Colorectal Cancer: A Randomized Phase\n3 Trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"issue":"3","key":"2026091407071843700_cit12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/abt\/tbaf014","article-title":"Structure\nand Function of Therapeutic Antibodies Approved by the US FDA in 2024","volume":"8","author":"Strohl","year":"2025","journal-title":"Antib. Ther."},{"issue":"12","key":"2026091407071843700_cit13","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody Tumor Penetration","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Delivery Rev."},{"issue":"9","key":"2026091407071843700_cit14","first-page":"2134","article-title":"Repopulation in\nMurine Breast Tumors during and after\nSequential Treatments with Cyclophosphamide and 5-Fluorouracil","volume":"63","author":"Wu","year":"2003","journal-title":"Cancer Res."},{"issue":"3","key":"2026091407071843700_cit15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118977","article-title":"A Mechanistic Tumor Penetration Model\nto Guide Antibody Drug Conjugate Design","volume":"10","author":"Vasalou","year":"2015","journal-title":"PLoS\nOne"},{"key":"2026091407071843700_cit16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jconrel.2018.06.016","article-title":"Influence of the Dissociation Rate Constant on the\nIntra-Tumor Distribution of Antibody-Drug Conjugate against Tissue\nFactor","volume":"284","author":"Tsumura","year":"2018","journal-title":"J. Controlled Release"},{"issue":"12","key":"2026091407071843700_cit17","first-page":"4750","article-title":"High Affinity\nRestricts\nthe Localization and Tumor Penetration of Single-Chain Fv Antibody\nMolecules","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res."},{"issue":"19","key":"2026091407071843700_cit18","first-page":"5144","article-title":"Micropharmacology\nof Monoclonal Antibodies in Solid Tumors: Direct Experimental Evidence\nfor a Binding Site Barrier","volume":"52","author":"Juweid","year":"1992","journal-title":"Cancer Res."},{"issue":"2","key":"2026091407071843700_cit19","doi-asserted-by":"publisher","first-page":"102104","DOI":"10.1016\/j.isci.2021.102104","article-title":"Dissecting\nthe Impact of Target-Binding Kinetics of Protein Binders on Tumor\nLocalization","volume":"24","author":"Song","year":"2021","journal-title":"iScience"},{"issue":"1","key":"2026091407071843700_cit20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1021\/acs.biomac.4c01303","article-title":"Binding Strength,\nNot\nValency, Dictates Accumulation and Penetration of Affinity Targeted\nMacromolecules into Solid Tumors","volume":"26","author":"Varanko","year":"2025","journal-title":"Biomacromolecules"},{"issue":"15","key":"2026091407071843700_cit21","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1158\/0008-5472.CAN-20-3822","article-title":"Transient\nCompetitive Inhibition\nBypasses the Binding Site Barrier to Improve Tumor Penetration of\nTrastuzumab and Enhance T-DM1 Efficacy","volume":"81","author":"Bordeau","year":"2021","journal-title":"Cancer\nRes."},{"issue":"2","key":"2026091407071843700_cit22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1208\/s12248-019-0387-x","article-title":"Antibody\nCoadministration as a Strategy to Overcome Binding-Site Barrier for\nADCs: A Quantitative Investigation","volume":"22","author":"Singh","year":"2020","journal-title":"AAPS J."},{"issue":"9","key":"2026091407071843700_cit23","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1158\/0008-5472.CAN-07-3018","article-title":"Quantitative Spatiotemporal\nAnalysis of Antibody Fragment\nDiffusion and Endocytic Consumption in Tumor Spheroids","volume":"68","author":"Thurber","year":"2008","journal-title":"Cancer Res."},{"issue":"37","key":"2026091407071843700_cit24","doi-asserted-by":"publisher","first-page":"11820","DOI":"10.1021\/jacs.8b07601","article-title":"Anti-EGFR Affibodies\nwith Site-Specific\nPhoto-Cross-Linker Incorporation Show Both Directed Target-Specific\nPhotoconjugation and Increased Retention in Tumors","volume":"140","author":"Brasino","year":"2018","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"2026091407071843700_cit25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/bit.27964","article-title":"Effect of Covalent Photoconjugation\nof Affibodies to Epidermal Growth Factor Receptor (EGFR) on Cellular\nQuiescence","volume":"119","author":"Roy","year":"2022","journal-title":"Biotechnol. Bioeng."},{"issue":"10","key":"2026091407071843700_cit26","doi-asserted-by":"publisher","first-page":"15873","DOI":"10.1021\/acsnano.2c02558","article-title":"Enzyme Prodrug Therapy\nwith Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting\nNanoparticles","volume":"16","author":"Roy","year":"2022","journal-title":"ACS Nano"},{"issue":"11","key":"2026091407071843700_cit27","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1021\/acs.biomac.4c01225","article-title":"Low-Affinity\nAffibodies Show Improved Transport and Retention in 3D Tumor Spheroids","volume":"25","author":"Bower","year":"2024","journal-title":"Biomacromolecules"},{"issue":"2","key":"2026091407071843700_cit28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jmb.2010.03.002","article-title":"Design of\nan Optimized Scaffold for Affibody Molecules","volume":"398","author":"Feldwisch","year":"2010","journal-title":"J. Mol. Biol."},{"issue":"9","key":"2026091407071843700_cit29","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/pro.2310","article-title":"Remarkable\nAlkaline Stability of an Engineered Protein A as Immunoglobulin Affinity\nLigand: C Domain Having Only One Amino Acid Substitution","volume":"22","author":"Minakuchi","year":"2013","journal-title":"Protein Sci. Publ. Protein Soc."},{"issue":"W1","key":"2026091407071843700_cit30","doi-asserted-by":"publisher","first-page":"W315","DOI":"10.1093\/nar\/gky497","article-title":"A Web Server for Accurate Protein Secondary Structure\nPrediction and Fold Recognition from the Circular Dichroism Spectra","volume":"46","author":"Micsonai","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"2026091407071843700_cit31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-03388-8","article-title":"Optimized\nSingle-Step Optical Clearing Solution for 3D Volume Imaging of Biological\nStructures","volume":"5","author":"Kim","year":"2022","journal-title":"Commun. Biol."},{"issue":"8016","key":"2026091407071843700_cit32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate Structure\nPrediction of\nBiomolecular Interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"34","key":"2026091407071843700_cit33","doi-asserted-by":"publisher","first-page":"15039","DOI":"10.1073\/pnas.1005025107","article-title":"Structural Basis for High-Affinity\nHER2 Receptor Binding\nby an Engineered Protein","volume":"107","author":"Eigenbrot","year":"2010","journal-title":"Proc. Natl. Acad.\nSci. U. S. A."},{"issue":"4","key":"2026091407071843700_cit34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural Basis for Inhibition of the Epidermal Growth\nFactor Receptor by Cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"issue":"16","key":"2026091407071843700_cit35","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.1021\/acs.jcim.4c00976","article-title":"Evaluation of AlphaFold\n3\u2032s Protein\u2013Protein\nComplexes for Predicting Binding Free Energy Changes upon Mutation","volume":"64","author":"Wee","year":"2024","journal-title":"J. Chem. Inf. Model."},{"issue":"7","key":"2026091407071843700_cit36","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/pro.5560040708","article-title":"N- and C-Capping Preferences for\nAll 20 Amino Acids\nin Alpha-Helical Peptides","volume":"4","author":"Doig","year":"1995","journal-title":"Protein Sci. Publ.\nProtein Soc."},{"issue":"1","key":"2026091407071843700_cit37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/pro.5560070103","article-title":"Helix Capping","volume":"7","author":"Aurora","year":"1998","journal-title":"Protein Sci. Publ.\nProtein Soc."},{"key":"2026091407071843700_cit38","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1016\/j.csbj.2021.05.048","article-title":"Binding\nCharacteristics of Staphylococcal\nProtein A and Streptococcal Protein G for Fragment Crystallizable\nPortion of Human Immunoglobulin G","volume":"19","author":"Lee","year":"2021","journal-title":"Comput. Struct.\nBiotechnol. J."},{"issue":"1","key":"2026091407071843700_cit39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/jmbi.1998.1843","article-title":"Anatomy of Hot Spots\nin Protein Interfaces1","volume":"280","author":"Bogan","year":"1998","journal-title":"J. Mol. Biol."},{"issue":"3","key":"2026091407071843700_cit40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7555\/JBR.36.20220003","article-title":"Improving Antibody\nAffinity through in Vitro Mutagenesis in Complementarity Determining\nRegions","volume":"36","author":"Ye","year":"2022","journal-title":"J. Biomed. Res."},{"issue":"9","key":"2026091407071843700_cit41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/protein\/gzx023","article-title":"Insights from engineering\nthe Affibody-Fc interaction with a computational-experimental method","volume":"30","author":"Nosrati","year":"2017","journal-title":"Protein Eng Des Sel."},{"issue":"1","key":"2026091407071843700_cit42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1158\/1078-0432.CCR-12-1258","article-title":"Diphtheria Toxin-Epidermal Growth\nFactor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer","volume":"19","author":"Yang","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"2","key":"2026091407071843700_cit43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.tips.2007.11.004","article-title":"Factors\nDetermining Antibody Distribution\nin Tumors","volume":"29","author":"Thurber","year":"2008","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Biomacromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.biomac.6c01111","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bomaf6\/article-pdf\/27\/9\/6134\/66882353\/acs.biomac.6c01111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bomaf6\/article-pdf\/27\/9\/6134\/66882353\/acs.biomac.6c01111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:11:34Z","timestamp":1789384294000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bomaf6\/article\/27\/9\/6134\/5276913\/Optimization-of-Affibody-Affinity-to-Improve"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,9,14]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.biomac.6c01111","relation":{},"ISSN":["1525-7797","1526-4602"],"issn-type":[{"value":"1525-7797","type":"print"},{"value":"1526-4602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}